Lymphoma

The Lymphoma Research Foundation formed a multidisciplinary consortium dedicated to advancing and harmonizing treatment for adolescents and young adults with lymphoma.

More evidence has emerged that T-cell lymphoma following chimeric antigen receptor T-cell therapy is both rare and not necessarily caused by the treatment.

Individuals with relapsed or refractory lymphoma who received chimeric antigen receptor T-cell therapy experienced a wide range of adverse events compared with those who received other treatments, study results showed.

In this video, Stephen M. Ansell, MD, PhD, discusses research presented at ASH Annual Meeting and Exposition on circulating tumor DNA.

Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving many cancers with high mortality rates and those affecting Black patients underfunded, study results in JCO Oncology Practice showed.

In this video, Stephen M. Ansell, MD, PhD, discusses research on the durability of bispecific antibodies, presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Limited duration loncastuximab tesirine in addition to rituximab appeared well tolerated and highly effective for relapsed or refractory follicular lymphoma, according to data presented at ASH Annual Meeting and Exposition.

In this video, Stephen M. Ansell, MD, PhD, discusses primary analysis results from the phase 3 Sympatico study.

SAN DIEGO — The volume of hematopoietic stem cell transplantation procedures for advanced diffuse large B-cell lymphoma has declined precipitously since 2019, study results presented at ASH Annual Meeting and Exhibition showed.

Researchers found lisocabtagene maraleucel to be a cost-effective second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma, study findings published in Blood Advances showed.